MED vs BFAM

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 14, 2026

MED

34.3
AI Score
VS
BFAM Wins

BFAM

42.9
AI Score

Investment Advisor Scores

MED

34score
Recommendation
SELL

BFAM

43score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MED BFAM Winner
Revenue 152.43M 1.49B BFAM
Net Income -5.22M 74.74M BFAM
Gross Margin 69.0% 23.6% MED
Net Margin -3.4% 5.0% BFAM
Operating Income -7.62M 144.77M BFAM
ROE -2.7% 7.9% BFAM
ROA -2.0% 2.0% BFAM
Total Assets 260.40M 3.79B BFAM
Cash 71.91M 163.69M BFAM
Current Ratio 4.86 0.48 MED
Free Cash Flow -108,000 163.71M BFAM

Relative Price Performance (Last 90 Days)

MED 1M: +26.5% · 3M: -5.4% BFAM 1M: -1.9% · 3M: +7.9%

Current Technical Phase

MED

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 58

RSI (14): 58.4 · Price: $11.95

BFAM

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 48

RSI (14): 48.5 · Price: $72.88

Fundamentals Snapshot

Metric MED BFAM
Market Cap
Forward P/E -42.7 12.4
Trailing P/E 23.4
Revenue (TTM)
Revenue Growth -0.3% 0.1%
Gross Margin 0.7% 0.3%
Operating Margin -0.1% 0.1%
EPS -2.34 3.15
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, BFAM is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.